Opaleye Management’s ProQR Therapeutics PRQR Stock Holding History

Opaleye Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-653,000	Closed	-$1.06M	–	49
2023 Q2	$1.06M	Hold	653,000	–	–	0.25%	41
2023 Q1	$1.39M	Sell	653,000 -807,000	-55%	-$2.47M	0.42%	39
2022 Q4	$5.4M	Sell	1,460,000 -1,655,000	-53%	-$2.17M	1.88%	17
2022 Q3	$2.32M	Buy	3,115,000 +375,000	+14%	+$301K	0.96%	25
2022 Q2	$2.13M	Buy	2,740,000 +315,000	+13%	+$235K	0.96%	27
2022 Q1	$2.19M	Buy	2,425,000 +989,490	+69%	+$3.31M	0.68%	34
2021 Q4	$11.5M	Buy	1,435,510 +11,310	+0.8%	+$86.1K	2.44%	14
2021 Q3	$11.9M	Buy	1,424,200 +43,800	+3%	+$286K	2.23%	15
2021 Q2	$9.3M	Buy	1,380,400 +77,400	+6%	+$499K	1.55%	21
2021 Q1	$8.61M	Buy	+1,303,000	New	+$6.66M	1.27%	22

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Opaleye Management's PRQR Position: Q3 2023 in Review

Opaleye Management sold out of ProQR Therapeutics (PRQR) in Q3 2023, closing a stake of 653,000 shares — an estimated $1.06M sold.

Opaleye Management first reported a position in PRQR in Q1 2021 and held it in 10 quarters. The position peaked at $11.9M in Q3 2021. 46 funds tracked by Wall St. Rank hold PRQR as of Q3 2023.

Opaleye Management reported no remaining ProQR Therapeutics position as of Q3 2023 after selling out during the quarter.
Opaleye Management sold 653,000 ProQR Therapeutics shares in Q3 2023, an estimated $1.06M.
Opaleye Management first reported a position in ProQR Therapeutics in Q1 2021 and held it in 10 quarters.
Opaleye Management's ProQR Therapeutics position peaked at $11.9M in Q3 2021.
46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2023.

Based on Opaleye Management's 13F filing for Q3 2023, filed 15 Nov 2023.